N/A N=55 Mindfulness to Reduce Loneliness in Older Caregivers
Social Isolation · Loneliness
Primary: Five Facet Mindfulness Questionnaire (FFMQ) — 137.83; 127.81; 137.42; 134.32 score on a scale
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
N/A N=310 CyberKnife Radiosurgery for Organ-Confined Prostate Cancer: Homogenous Dose Distribution
Prostate Cancer · Prostatic Cancer · Prostate Neoplasms
Primary: Risk for Gastrointestinal (GI) and Genitourinary (GU) Toxicity — 0; 0; 0; 1.5 percentage of participants
Phase 1 N=5 Transfusion of Biotinylated Red Blood Cells
Anemia
Primary: Number of Participants That Had bRBC Detectable at 70 Days Post-intervention — 5 participants
Phase 1 N=14 A Study of a Single Dose of ALXN1210 in Healthy Participants
Healthy
Primary: Number of Participants With Treatment Emergent Adverse Events (TEAEs) — 3; 4; 4 Participants
Phase 2 N=80 Study of Pembrolizumab in Subjects With Advanced Gastric or Gastroesophageal Junction Adenocarcinoma Who Progressed After First-Line Therapy With Platinum and Fluoropyrimidine: Integration of Molecular Subtypes Through Integrative Genomic Analysis
Gastric Adenocarcinoma · Gastroesophageal Junction Adenocarcinoma
Primary: RR — 15 Participants
N/A N=167 Mobile Health Case Management System for Reducing Pediatric Treatment Abandonment
Burkitt Lymphoma · Retinoblastoma · Diffuse Large B-cell Lymphoma
Primary: Protocol Compliance as Measured by Percent Compliance to Prescribed Chemotherapy — 73.8; 96.0; 50.0; 74.9 percentage of compliance — p=<0.001
Phase 2 N=105 A Phase II Study in Adult Patients With Moderate to Severe Atopic Dermatitis
Atopic Dermatitis
Primary: The Percentage of Subjects Achieving Investigator's Global Assessment (IGA) Response Which Improvement ≥ 2 From Baseline. — 9; 19; 2 Participants
Phase 1 N=69 Study to Evaluate Safety, Tolerability, and Pharmacokinetics of Minocin (Minocycline) for Injection in Healthy Adults
Normal Healthy Volunteers
Primary: Number Of Participants Experiencing Treatment-emergent Adverse Events — 0; 0; 0; 0 participants
Phase 1 N=12 Defibrotide Therapy for SARS-CoV2 (COVID-19) Acute Respiratory Distress Syndrome (ARDS)
COVID · Sars-CoV2 · COVID-19
Primary: Number of Major Hemorrhagic Complications Within 14 Days of Initiation of Treatment — 0 Participants
Phase 2 N=10 TAK-228 and TAK-117 Followed by Cisplatin and Nab Paclitaxel for Metastatic Triple Negative Breast Cancer
Triple Negative Breast Cancer
Primary: Efficacy (Objective Response Rate) — 1 Participants
N/A N=3,587 Working With HIV Clinics to Adopt Addiction Treatments Using Implementation Facilitation
Substance-related Disorders
Primary: Change in Provision of Addiction Treatments — 66; 20; 268; 33 Participants — p=0.55
Phase 3 N=690 Olanzapine With or Without Fosaprepitant Dimeglumine in Preventing Chemotherapy Induced Nausea and Vomiting in Cancer Patients Receiving Highly Emetogenic Chemotherapy
Malignant Neoplasm
Primary: No Nausea Rate Defined as a Response of 0 in the Nausea Item of Nausea and Vomiting Daily Diary/Questionnaire in the Overall (0-120 Hours), Acute (0-24 Hours), and…
N/A N=1,398 Study Comparing the MiStent SES Versus the XIENCE EES Stent
Coronary Stenosis
Primary: Number of Participants With Occurrence of a Device Oriented Composite Endpoint (DOCE) — 40; 45 Participants
N/A N=31 Neuromodulation of Cognition in Older Adults
Healthy
Primary: Change in NIH Toolbox Fluid Cognition Composite Score — 4.7; 6.1 units on a scale
Phase 3 N=326 Efficacy and Safety of IDP-124 Lotion for the Treatment of Moderate to Severe Atopic Dermatitis in Pediatric and Adult Subjects
Atopic Dermatitis
Primary: Percentage of Participants Who Had at Least a 2-grade Reduction From Baseline at Week 6 in the Investigator Global Assessment (IGA) Scale and Had an IGA at Week 6 That…